List view / Grid view
25 August 2011 | By Eli Lilly and Company, Boehringer Ingelheim
Linagliptin is the only DPP-4 inhibitor to be approved at one dosage strength for adults with type 2 diabetes in Europe, without any need for dose adjustments...
25 August 2011 | By Boehringer Ingelheim
Marketing Authorisation from the European Commission for Trajenta® (linagliptin)...
10 August 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and ProBioGen AG have signed a non-exclusive Licensing Agreement regarding ProBioGen’s GlymaxX® technology...
9 August 2011 | By Boehringer Ingelheim
The pharmaceutical company Boehringer Ingelheim has in the first half of 2011 once again grown in local currency terms compared to the previous year (+ 4 percent). Due to negative foreign exchange effects, consolidation in euros shows growth of 2.6 percent, with total net sales of EUR 6.4 billion against…
4 August 2011 | By Ogilvy Healthworld UK Limited
Pradaxa®1 (dabigatran etexilate) approved...
27 July 2011 | By Boehringer Ingelheim
The CHMP issued a Positive Opinion recommending the approval of Viramune® (nevirapine)...
6 July 2011 | By Boehringer Ingelheim
The www.changemakers.com/morehealth competition launched...
24 June 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly received a positive opinion from the EMA's medicinal committee...
20 June 2011 | By Boehringer Ingelheim
To round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill & finish for biopharmaceuticals at their state-of-the-art facility in Biberach, Germany, with a new filling line.
17 June 2011 | By Boehringer Ingelheim
TWYNSTA® leads to prompt and very effective reductions in blood pressure...
16 June 2011 | By Boehringer Ingelheim
For dual-acting glucagon and GLP-1 receptor agonists...
9 May 2011 | By Evotec AG
Twelfth milestone triggers payment of EUR 2 million to Evotec...
3 May 2011 | By OgilvyHealthPR
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…
Yesterday Boehringer Ingelheim formally acquired Amgen’s biopharmaceutical development and manufacturing facility in Fremont, California (USA)...
9 February 2011 | By Boehringer Ingelheim
Announcement covers global technical development and manufacturing for antibody-based therapeutics...
